ADVI’s Marc Samuels, featured in Pink Sheet, gives his thoughts on MEDCAC’s upcoming review of CAR-T drug outcomes
Questions to the panel “are broadly relevant to cancer and not specific to CAR-T therapeutics,” Marc Samuels, CEO of the health care consultancy ADVI, commented. “This interest in cancer PROs is consistent with CMS’ interest in PROs for vascular and other diseases as articulated in other historical MedCACs.” However, Samuels added, “the panel can go wherever the day takes them; so this could also be the opening act.”
[el-text]
Written by Cathy Kelly
***excerpt***
Questions to the panel “are broadly relevant to cancer and not specific to CAR-T therapeutics,” Marc Samuels, CEO of the health care consultancy ADVI, commented. “This interest in cancer PROs is consistent with CMS’ interest in PROs for vascular and other diseases as articulated in other historical MedCACs.” However, Samuels added, “the panel can go wherever the day takes them; so this could also be the opening act.”
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.